Locoregional adverse effects of cancer therapy in women with advanced breast cancer
An integrative review
DOI:
https://doi.org/10.35699/2316-9389.2022.40564Keywords:
Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Agents, Evidence-Based Practice, NursingAbstract
Objective: to identify the locoregional adverse effects of administering intravenous oncologic therapy in women with advanced breast cancer. Method: this was an integrative literature review using the PubMed/MEDLINE, CINAHL, LILACS, and EMBASE databases, without a time cut, in addition to a reverse search of the selected articles updated until May 2022. The population included women with advanced breast cancer undergoing intervention with intravenous oncologic therapy with chemotherapy, hormone therapy, or monoclonal antibody, and the outcome assessed locoregional adverse effects. Results: 2,789 studies were identified, and the final sample consisted of 8 clinical trials and 1 retrospective observational study, all of which were international studies published from 1986 to 2018. Predominantly, patients with stage IV breast cancer, were aged 50 years or older, and had multiple metastases. Locoregional adverse effects were phlebitis, ulceration and/or necrosis, pain, erythema, and unspecified injection site reaction. The studies did not detail the type of venous catheter, the osmolarity of the drugs, and preventive care to reduce these adverse effects. Conclusion: The evidence from these articles showed that locoregional adverse effects are present in efficacy research of oncologic drugs in women with advanced breast cancer. Nonetheless, the safety of administering cancer drugs is not elucidated in this review, indicating the need for follow-up studies of adverse effects.
Downloads
References
Huang J, Chan PS, Lok V, Chen X, Ding H, Jin Y, et al. Global incidence and mortality of breast cancer: a trend analysis. Aging (Albany, N.Y. Online). 2021[citado 2021 out. 25];13(4):5748-803. Disponível em: https://www.aging-us.com/article/202502/pdf
Instituto Nacional do Câncer. ABC do câncer: Síntese de dados dos sistemas de informação. Abordagens básicas para o controle do câncer. 6ªth rev. ed. Rio de Janeiro: INCA; 2020[citado 2020 jul. 08]. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//livro-abc-6-edicao-2020.pdf
Instituto Nacional do Câncer. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: Ministério da Saúde; 2019[citado 2020 jul. 10]. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf
Katsura C, Ogunmwonyi I, Kankam H, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond). 2022[citado em 2022 jan. 15];83(2):1-7. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35243878/
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [Internet]: NCCN Clinical Practice Guidelines in Oncology : Breast Cancer; 2020[citado 2020 maio 8].4: 1-233. Disponível em: https://www2.tri-kobe.org/nccn/guideline/breast/english/breast.pdf
Frasson AL, Millen E, Brenelli F, Luzzatto F, Berrettini Jr A, Cavalcante FP, et al., (editores). Doenças da Mama: guia de bolso baseado em evidências. Rio de Janeiro: Atheneu; 2018.
Lima EOL, Silva MM. Quality of life of women with locally advanced or metastatic breast cancer. Rev. Gaúcha Enferm. [Internet]. 2020[citado 2022 mar. 16]; 41:e20190292. Disponível em: http://dx.doi.org/10.1590/1983-1447.2020.20190292
Sociedade Brasileira de Oncologia Clínica. Carcinoma de mama. 2020[citado 2020 jul. 14];66. Disponível em: https://sboc.org.br/images/diretrizes/diretrizes_pdfs/Carcinoma_de_Mama.pdf.
Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019;7(1):3-23.
Jorge JJ. Imunoterapia no tratamento do câncer. Arq Asma Alerg Imunol. 2019;3(2):133-8.
Rashid N, Koh HA, Baca Hilda C, Li Z, Malecha S, Abidoye O, Masaquel A. Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System. J Manag Care Spec Pharm. 2015 Oct; 21(10):863-71. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26402387/
Custódio CS. Injúrias vasculares relacionadas à infusão periférica de quimioterapia em mulheres com câncer de mama: estudo longitudinal. Dissertação [Mestrado em Enfermagem]. Universidade Federal de Brasília; 2016.
Custódio CS, Goulart CB, Reis PED, Silveira RCCP, Santos BN, Silva KRM, Vasques CI. Acessos vasculares em oncologia. [place unknown: publisher unknown]; 2019. Diretrizes Oncológicas: Câncer de mama; [citado 2020 jul. 11]; 641-52. Disponível em: https://diretrizesoncologicas.com.br/wp-content/uploads/2018/10/Diretrizes-oncol%C3%B3gicas-2_Parte40.pdf
Oliveira PP, Santos VEP, Bezerril MS, Andrade FB, Paiva RM, Silveira EAA. Segurança do paciente na administração de quimioterapia antineoplásica e imunoterápicos para tratamento oncológico: scoping review. Texto Contexto Enferm. 2019[citado 2021 nov. 10];28:1-18. Disponível em: https://doi.org/10.1590/1980-265X-TCE-2018-0312
Conselho Federal de Enfermagem. Resolução Cofen nº 569, 2018[citado 2022 mar. 22]. Disponível em: http://www.cofen.gov.br/resolucao-cofen-no-0569-2018_60766.html/print/
Oliveira PP, Santos VEP, Bezerril MS, Andrade FB, Paiva RM, Silveira EAA. Segurança do paciente na administração de quimioterapia antineoplásica e imunoterápicos para tratamento oncológico: scoping review. Texto Contexto Enferm. 2019[citado 2022 mar. 22]; 28: e20180312. Disponível em: http://dx.doi. org/10.1590/1980-265X-TCE-2018-0312
Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na Enfermagem. Texto Contexto Enferm. 2008[citado em 2020 out. 15];17(4):758-64. Disponível em: https://www.scielo.br/pdf/tce/v17n4/18.pdf
Santos CMC, Pimenta CAM, Nobre MRC. The PICO strategy for the research question construction and evidence search. Rev Latino-Am Enferm. 2007[citado 2022 mar. 22];15(3):508-11.Disponível em: https://doi.org/10.1590/S0104-11692007000300023
Joanna Briggs Institute (JBI). Checklist for Randomized Controlled Trials. 2017[citado em 2021 dez. 21]. Disponível em: https://jbi.global/sites/default/files/2019-05/JBI_RCTs_Appraisal_tool2017_0.pdf
Joanna Briggs Institute (JBI). Checklist for Cohort Studies. [citado em 2021 dez. 21]. Disponível em https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Cohort_Studies2017_0.pdf
Polmann H, Melo G, Conti Réus J, Domingos FL, de Souza BDM, Padilha AC, et al. Prevalence of dentofacial injuries among combat sports practitioners: a systematic review and meta-analysis. Dent Traumatol. 2020[citado em 2021 dez. 25];36(2):124-40. Disponível em: doi 10.1111/edt.12508
Dang D, Dearholt SL. Johns Hopkins nursing evidence-based practice: model & guidelines.3rd ed. Indianápolis: Sigma Theta Tau International; 2018.
Holmes FA, Esparza L, Yap HY, Buzdar AU, Blumenschein GR, Hortobagyi GN. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1986[citado 2021 nov. 10];18(2):157-61. Disponível em: doi: 10.1007/BF00262287
Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997[citado 2021 nov. 10];15(4):1318-32. Disponível em: doi: 10.1200/JCO.1997.15.4.1318
Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999[citado 2021 nov. 10];17(5):1413-24. Disponível em: doi: 10.1200/JCO.1999.17.5.1413
. Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004[citado 2021 nov. 10];15(10):1527-34. Disponível em: doi: 10.1093/annonc/mdh393
Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjöström J, Kjaer M. Scandinavian Breast Group Trial (SBG9403). Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol. 2004[citado 2021 nov. 10];22(12):2313-20. Disponível em: doi: 10.1200/JCO.2004.11.503.
Irvin WJ Jr, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, et al. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer. 2010[citado 2021 nov. 10];10(6):465-70. Disponível em: doi: 10.3816/CBC.2010.n.061
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015[citado 2021 nov. 10];16(7):816-29. Disponível em: doi: 10.1016/S1470-2045(15)00051-0
Wang J, Zheng R, Wang Z, Yang Y, Wang M, Zou W. Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes. Med Sci Monit. 2017[citado 2021 nov. 10];23:4657-64. Disponível em: doi: 10.12659/msm.905300
Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, et al. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2018[citado 2021 nov. 10];29(4):881-7. Disponível em: doi: 10.1093/annonc/mdy051
Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017[citado 2021 nov 10];95:1209-18. Disponível em doi: 10.1016/j.biopha.2017.09.059
Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol. 1998[citado 2021 nov. 10];25(4 Suppl 10):43-7. Disponível em: https://pubmed.ncbi.nlm.nih.gov/9768823/
Freitas KABS, Popim RC. Manual de extravasamento de antineoplásicos. Botucatu: Hospital das Clínicas da Faculdade de Medicina de Botucatu; 2021. p. 1-41.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Cancer Therapy Evaluation Program. 2020[citado 2021 jul. 31]. Disponível em: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60
World Health Organization. WHO Handbook for reporting results of cancer treatment. WHO offset publication. 1979[citado 2021 jul. 31]48:1-46. Disponível em: http://apps.who.int/iris/bitstream/handle/10665/37200/WHO_OFFSET_48.pdf?sequence=1
Camp-Sorrell D, Matey L, editors. Access device standards of practice for oncology nursing. Pittsburgh, PA: Oncology Nursing Society; 2017. Disponível em https://www.ons.org/sites/default/files/publication_pdfs/Pages%20from%20ADS_12-21%20(002).pdf
Agência Nacional de Vigilância Sanitária. Gerência de Vigilância e Monitoramento em Serviços de Saúde (GVIMS) Gerência Geral de Tecnologia em Serviços de Saúde (GGTES) Medidas de Prevenção de Infecção Relacionada à Assistência à Saúde. Brasília: Anvisa. 2017[citado 2021 jul. 31];(2):122. Disponível em: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=pCiWUy84%2BR0%3D
Polo LHV, Moraes MW. Performance de Zubrod e Índice de Karnofsky na avaliação da qualidade de vida de crianças oncológicas. Einstein. 2009[citado 2021 jul. 31];7(3 Pt 1):314-21. Disponível em: http://apps.einstein.br/revista/arquivos/PDF/1241-Einstein%20v7n3p314-21_port.pdf
Bertoglio S, van Boxtel T, Goossens GA, Dougherty L, Furtwangler R, Lennan E, et al. Improving outcomes of short peripheral vascular access in oncology and chemotherapy administration. J Vasc Access. 2017[citado 2021 nov. 10];18(2):89-96. Disponível em: doi: 10.5301/jva.5000668
Additional Files
Published
Issue
Section
License
Copyright (c) 2022 REME-Revista Mineira de Enfermagem
This work is licensed under a Creative Commons Attribution 4.0 International License.
Links
Facebook
Instagram
Twitter
